1 2 3 4 5

Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives

Seng, Rémonie; Ghislain, Mathilde; Girard, Pierre-Marie; More

AIDS . 31(9):1323-1332, June 1, 2017.

Likely effect of the 2014 Ebola epidemic on HIV care in Liberia

Loubet, Paul; Mabileau, Guillaume; Baysah, Maima; More

AIDS . 29(17):2347-2351, November 2015.

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults

Sloan, Caroline E.; Champenois, Karen; Choisy, Philippe; More

AIDS . 26(1):45-56, January 2, 2012.

Reply to comment on ‘pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’

Barrail-Tran, Aurélie; Yazdanpanah, Yazdan; Goldwirt, Lauriane; More

AIDS . 25(7):1011-1012, April 24, 2011.

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

Charpentier, Charlotte; Roquebert, Bénédicte; Colin, Céline; More

AIDS . 24(17):2651-2656, November 13, 2010.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

Barrail-Tran, Aurélie; Yazdanpanah, Yazdan; Goldwirt, Lauriane; More

AIDS . 24(16):2581-2583, October 23, 2010.

HIV drug resistance surveillance for prioritizing treatment in resource-limited settings

Walensky, Rochelle P; Weinstein, Milton C; Yazdanpanah, Yazdan; More

AIDS . 21(8):973-982, May 11, 2007.

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d’Ivoire: a trial-based analysis

Yazdanpanah, Yazdan; Losina, Elena; Anglaret, Xavier; More

AIDS . 19(12):1299-1308, August 12, 2005.

1 2 3 4 5